OTCMKTS:RGBP Regen BioPharma (RGBP) Stock Price, News & Analysis $0.0001 0.00 (0.00%) As of 02:57 PM Eastern Add Compare Share Share Stock Analysis Stock AnalysisChartSEC FilingsBuy This Stock About Regen BioPharma Stock (OTCMKTS:RGBP) View Price History Chart DataSkip Price History Chart 1 Day 5 Days 30 Days 90 Days 1 Year Advanced 1 Day 1 Day 5 Days 30 Days 90 Days 1 Year Advanced Show volume Show extended hours Get Regen BioPharma alerts:Sign Up Key Stats Today's Range$0.0001▼$0.000250-Day Range N/A52-Week Range$0.00▼$0.10Volume4.61 million shsAverage Volume18.62 million shsMarket CapitalizationN/AP/E RatioN/ADividend YieldN/APrice TargetN/AConsensus RatingN/A Company Overview Regen BioPharma, Inc. is a development‐stage biotechnology company focused on advancing regenerative medicine and immunotherapy products through stem cell science. The company’s research efforts center on identifying and developing novel therapeutic candidates that harness the regenerative potential of adult and embryonic stem cells, with an emphasis on cancer, infectious and autoimmune diseases. Its primary activities include the discovery and preclinical validation of stem cell‐derived receptors and peptides, the development of immuno‐oncology assets, and the filing of investigational new drug (IND) applications to support first‐in‐human studies. Regen BioPharma holds a portfolio of patents covering modified stem cell lines and proprietary methods for directing cell differentiation and modulating immune responses. Founded in the mid‐1990s and headquartered in West Newton, Massachusetts, Regen BioPharma operates as a fully integrated research organization. The company collaborates with academic institutions, contract research organizations and industry partners across North America to advance its therapeutic programs. Regen BioPharma’s leadership team comprises seasoned executives and scientific advisors with backgrounds in biotechnology R&D, clinical development and patent strategy.AI Generated. May Contain Errors. Read More Receive RGBP Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Regen BioPharma and its competitors with MarketBeat's FREE daily newsletter. Submit View SMS TermsSMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy. RGBP Stock News HeadlinesRegen BioPharma Update on Orphan Drug Application for HemaXellerate Will Be Presented At Emerging Growth Conference on September 24, 2025September 23, 2025 | finance.yahoo.comRegen BioPharma Prepares Response For FDA Regarding Its Orphan Drug Application for HemaXellerateSeptember 16, 2025 | finance.yahoo.comA letter from Shannon StansberryPorter Stansberry nearly canceled the entire project. When he first saw the claimed returns - only one down year in nearly two decades and total gains of almost 2,000% - his immediate reaction was disbelief. It took a trusted friend's personal vouching for Emmet Savage and a face-to-face trip to Ireland to change his mind. The full documentary, Investigating Project Prophet, is now live.July 22 at 1:00 AM | Porter & Company (Ad)Regen BioPharma Explores Expanded Use of HemaXellerate for Chemotherapy-Induced Bone Marrow SuppressionSeptember 4, 2025 | tmcnet.comRegen Biopharma Signs Convertible Note AgreementAugust 19, 2025 | theglobeandmail.comRegen BioPharma Discusses Potential Impact of HemaXellerate on Chemotherapy Treament MarketAugust 15, 2025 | finance.yahoo.comRegen BioPharma, Inc. to Seek Orphan Drug Designation for Lead ProductJuly 24, 2025 | finance.yahoo.comRegen BioPharma, Inc. (RGBP) - Yahoo FinanceJuly 9, 2025 | finance.yahoo.comSee More Headlines RGBP Stock Analysis - Frequently Asked Questions How have RGBP shares performed this year? Regen BioPharma's stock was trading at $0.0074 at the beginning of the year. Since then, RGBP stock has decreased by 98.6% and is now trading at $0.0001. When did Regen BioPharma's stock split? Regen BioPharma shares split on the morning of Thursday, June 20th 2024.The 3-1 split was announced on Thursday, June 20th 2024. The newly minted shares were payable to shareholders after the closing bell on Thursday, June 20th 2024. An investor that had 100 shares of stock prior to the split would have 300 shares after the split. How do I buy shares of Regen BioPharma? Shares of RGBP stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. What other stocks do shareholders of Regen BioPharma own? Based on aggregate information from My MarketBeat watchlists, some other companies that Regen BioPharma investors own include Meta Platforms (META), Trans Global Group (TGGI), Exxe Group (AXXA), DraftKings (DKNG), Enzolytics (ENZC), Alcoa (AA) and Airborne Wireless Network (ABWN). Industry, Sector and Symbol Stock ExchangeOTCMKTS SectorMedical Industry Biotechnology Sub-IndustryPharmaceutical Products Current SymbolOTCMKTS:RGBP CIK1589150 Webwww.regenbiopharmainc.com Phone(619) 722-5505FaxN/AEmployees1Year FoundedN/AProfitability EPS (Trailing Twelve Months)N/A Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet IncomeN/A Net MarginsN/A Pretax MarginN/A Return on EquityN/A Return on AssetsN/A Debt Debt-to-Equity RatioN/A Current RatioN/A Quick RatioN/A Sales & Book Value Annual SalesN/A Price / SalesN/A Cash FlowN/A Price / Cash FlowN/A Book ValueN/A Price / BookN/AMiscellaneous Outstanding SharesN/AFree FloatN/AMarket CapN/A OptionableNot Optionable BetaN/A 10 Stocks Powering The Next AI Boom The AI boom is creating opportunities across semiconductors, cloud computing, enterprise software, infrastructure, cybersecurity, and automation. Inside this report, you’ll find 10 companies positioned to benefit as artificial intelligence moves from hype to real-world deployment and becomes a core growth driver for corporate America.Get This Free Report This page (OTCMKTS:RGBP) was last updated on 7/22/2026 by MarketBeat.com Staff. From Our PartnersAmerica’s answer to universal basic incomeRobert Kiyosaki, author of Rich Dad Poor Dad, is highlighting an income strategy he calls the Patriot Income P...Freedom Financial | SponsoredSmall Colorado Company (Backed by Sam Altman) Could Save U.S. Power GridA small Colorado company has secured rights to technology that could prevent the U.S. public power grid from c...Altimetry | SponsoredBlackRock is hoarding it. JPMorgan is hoarding it. Do you own it?BlackRock, JPMorgan, Goldman Sachs, and Fidelity are reportedly accumulating a scarce blockchain asset - one t...Awesomely | SponsoredTSM just handed Trump's secretive AI project $100 billionTaiwan Semiconductor just committed another $100 billion to U.S. chip manufacturing - on top of $165 billion a...InvestorPlace | SponsoredThe Starlink of EnergyA portable energy unit - already used by the U.S. Navy for decades - is now drawing serious attention from Big...Monument Traders Alliance | SponsoredElon is about to dominate the biggest arms race in tech historyMicrosoft, Amazon, Alphabet, and Meta have collectively poured nearly $700 billion into AI infrastructure in 2...The Oxford Club | SponsoredIt all happens tonight.Tonight, trader Sean Allison is hosting a live session to walk through his Zero-Dollar Trade Advantage strateg...Trade Thirsty | SponsoredThe options guide that actually starts at the beginningMost options educators jump straight into Greeks, spreads, and implied volatility - losing beginners before th...Base Camp Trading | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Regen BioPharma, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Regen BioPharma With A Colleague Link copied to clipboard. Unlock superior investment research and tools. Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools and reports. Get MarketBeat All Access MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In Email Me a Login Link or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
